Company Aggregate Debt: protaratx.com (TARA)
The market price chart on the GURU.Markets platform for Protara Therapeutics (TARA) demonstrates a debt load of 0.00. This biotech business lacks a stable cash flow, meaning its viability relies exclusively on external investments. Protara Therapeutics (TARA) operates in the oncology sector, developing cutting-edge therapies. The primary development vector is focused on bringing TARA-002 to market for the treatment of bladder and lymphatic pathologies.
%3A%20Company%20Aggregate%20Debts&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_TARA_-_Protara-Therapeutics_-_Company-Aggregate-Debts "Protara Therapeutics Inc - TARA Company Total Debt (period 07/04/2022 - 10/28/2026) | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Protara Therapeutics, Inc. (TARA)
Investors are seeking fundamental stability pillars through an analysis of debt load. This metric aggregates all business obligations, measuring the total volume of borrowed funds. The dynamics of the company's credit portfolio reflect the balance between securing liquidity and settling liabilities. For Protara Therapeutics (TARA), this indicator is critical due to the absence of revenue. High risks of Chariot clinical trial failure make any debt a dangerous factor, increasing the probability of dilutive issuances.